✦ LIBER ✦

Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis

✍ Scribed by Stefano Capri; Walter Ageno; Davide Imberti; Gualtiero Palareti; Franco Piovella; Gianluigi Scannapieco; Marco Moia

Book ID: 107481316
Publisher: Springer Milan
Year: 2009
Tongue: English
Weight: 286 KB
Volume: 5
Category: Article
ISSN: 1828-0447
DOI: 10.1007/s11739-009-0324-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmaco-economics and decision making i

Pharmaco-economics and decision making in health care. The case of “extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis”

✍ Rosanna Tarricone 📂 Article 📅 2011 🏛 Springer Milan 🌐 English ⚖ 95 KB

Cost-Effectiveness of Fondaparinux Compa

Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery

✍ Sean D. Sullivan; Louis Kwong; Edith Nutescu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

Cost-effectiveness of extended prophylax

Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery

✍ Jonas Lundkvist; David Bergqvist; Bengt Jönsson 📂 Article 📅 2007 🏛 Springer 🌐 French ⚖ 157 KB

Cost and occurrence of thrombocytopenia

Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries

✍ Laura Elizabeth Happe; Eileen Marie Farrelly; Richard H. Stanford; Matt William 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 275 KB

The prophylaxis of venous thrombosis in

The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options

✍ Giancarlo Agnelli; Joseph A. Caprini 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## Abstract Cancer is a risk factor for venous thromboembolism (VTE). This risk is amplified by treatment with chemotherapy, radiation, or surgery. Thus, patients with cancer undergoing major surgery should receive appropriate prophylaxis. Available agents include low‐dose unfractionated heparin (L